

IN THE CLAIMS

Please cancel Claims 1-3 and 10-11.

Please amend the claims as shown on the attached marked-up copy to read as follows:

--4. (Amended) A method for screening and for selecting antiparasitic agents, herbicides or combinations thereof, comprising

-incubating a substance to be tested with an MGDG synthase or with a plastidial membrane isolated from a plant, and

-measuring the specific enzymatic activity, after said incubation.

5. (Amended) The method as claimed in claim 4, wherein said MGDG synthase has an initial specific activity of between 0.1 and 120 μ mol of galactose incorporated/h/mg of protein.

6. (Amended) The method as claimed in claim 4, wherein the MGDG synthase/substance to be tested incubation is carried out in an incubation medium containing a buffer adjusted to a pH of between 6 and 9, in the presence of detergents, a reducing agent, phosphatidylglycerol, a salt or combinations thereof.

7. (Amended) The method as claimed in claim 6, wherein the incubation medium further comprises 50 mM of MOPS-NaOH, 4.5 mM of CHAPS, 1 mM of DTT, 1.3 mM of phosphatidylglycerol, 250 mM of $\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$ and 250 mM of KCl, and has a pH of 7.8

8. (Amended) The method according to claim 4, wherein the MGDG synthase is of plant origin and is selected from the group consisting of the purified MGDG synthases A, recombinant MGDG synthases A, purified MGDG synthases B, and recombinant MGDG synthases B.

9. (Amended) The method as claimed in claim 4, wherein said apicomplex parasite is selected from the group consisting of *Plasmodium*, *Toxoplasma* and *Eimeria*.--

Please add new Claims 12-17 as follows:

--12. (New) A pharmaceutical composition comprising an MGDG synthase inhibitor and a pharmaceutically-acceptable carrier or excipient.